IRIS
DE MARTINO, MARIA CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.067
EU - Europa 632
AS - Asia 176
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.889
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.036
IT - Italia 168
CN - Cina 139
NL - Olanda 103
SE - Svezia 83
FR - Francia 65
IE - Irlanda 63
FI - Finlandia 53
UA - Ucraina 41
DE - Germania 33
CA - Canada 31
IN - India 16
CI - Costa d'Avorio 11
GB - Regno Unito 11
IR - Iran 9
SG - Singapore 9
ES - Italia 4
TR - Turchia 3
CZ - Repubblica Ceca 2
GR - Grecia 2
RO - Romania 2
BE - Belgio 1
EC - Ecuador 1
EG - Egitto 1
EU - Europa 1
NO - Norvegia 1
Totale 1.889
Salva come PNG Salva come JPEG
Città #
Chandler 258
Amsterdam 98
Millbury 70
Princeton 54
Jacksonville 53
Nanjing 45
Wilmington 43
Naples 40
Ashburn 34
Beijing 34
Napoli 31
Boston 28
Ottawa 28
Des Moines 20
Falls Church 19
Woodbridge 16
Hebei 13
Houston 13
Nanchang 12
San Mateo 12
Lawrence 9
Seattle 9
Shenyang 9
Dearborn 7
Portici 7
Ardabil 6
Boardman 6
Catania 6
Pune 6
Singapore 6
Kronberg 5
Marigliano 5
Norwalk 5
Changsha 4
Jiaxing 4
Leawood 4
Tianjin 4
Augusta 3
Campobasso 3
Dogliani 3
Dublin 3
Florence 3
Kunming 3
New York 3
Pisa 3
Rome 3
Schio 3
Toronto 3
Acerra 2
Ann Arbor 2
Athens 2
Buffalo 2
Casalecchio Di Reno 2
Castellammare di Stabia 2
Mumbai 2
Pittsburgh 2
Prague 2
Redmond 2
Sant'Ilario d'Enza 2
Tappahannock 2
Villa Literno 2
Afragola 1
Ailano 1
Altamura 1
Avella 1
Avellino 1
Bangalore 1
Barcelona 1
Bremen 1
Brussels 1
Cairo 1
Caserta 1
Fairfield 1
Fuzhou 1
Hangzhou 1
Horia 1
Indiana 1
Krefeld 1
Lanzhou 1
Lappeenranta 1
London 1
Manta 1
Mascalucia 1
Middletown 1
Monmouth Junction 1
Monza 1
Mugnano Di Napoli 1
Ningbo 1
Orange 1
Oslo 1
Redwood City 1
San Diego 1
San Francisco 1
Sant'arpino 1
Segrate 1
Washington 1
Yellow Springs 1
Totale 1.118
Salva come PNG Salva come JPEG
Nome #
Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age 77
Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly 58
Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism 57
Weekly clodronate treatment prevents bone loss and vertebral fractures in womenwith subclinical Cushing's syndrome. 56
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance 54
Neuropsychiatric disorders in Cushing's syndrome. 53
Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease 53
The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. 51
Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly 47
Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status 46
Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance 44
Comment on Azmahani et al. "Steroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditions" 43
The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. 42
Erratum to: The treatment with pasireotide in Cushing’s disease: effects of long–term treatment on tumor mass in the experience of a single center (Endocrine, (2015), 50, (725-740) DOI 10.1007/s12020-015-0557-2) 42
Metabolic alterations and cardiovascular outcomes of cortisol excess 41
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma 41
Complications of Cushing's syndrome: State of the art 41
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit 40
Cushing's syndrome: aftermath of the cure. 39
Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission 38
Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head-to-head study 37
Cushing's syndrome 36
An evaluation of patients with hyperprolactinemia: have dynamic tests had their day? 35
Cardiovascular disease in Cushing's syndrome: heart versus vasculature. 35
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study 35
Cushing’s disease: the burden of illness 35
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. 34
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting 34
CORTISOL CIRCADIAN RHYTHM AND INSULIN RESISTANCE IN MUSCLE: EFFECT OF DOSING AND TIMING OF HYDROCORTISONE EXPOSURE ON INSULIN SENSITIVITY IN SYNCHRONIZED MUSCLE CELLS 34
Pathophysiology of diabetes mellitus in Cushing's syndrome. 31
Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. 31
Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. 30
Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. 28
The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery 28
Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. 28
Severe systemic complications of acromegaly 26
The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs 26
Effect of the acute administration of the Dopamine Agonist Cabergoline on glucose tolerance and Insuline Sensitivity in patient with obesity. 26
The dopaminergic control of Cushing's syndrome 26
Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells 25
Is mortality in Cushing's disease reversible with remission? 25
The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. 24
The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states 23
Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials 23
Six controversial issues on subclinical Cushing’s syndrome 22
TREATMENT WITH GROWTH HORMONE RECEPTOR ANTAGONIST IN ACROMEGALY: EFFECT ON CARDIAC ARRHYTHMIAS. 21
The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center 21
The role of somatostatin receptors in the medical treatment of acromegaly 20
New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours 20
Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. 20
Erratum to: Pituitary tumors and pregnancy: The interplay between a pathologic condition and a physiologic status (Journal of Endocrinological Investigation (2014) 37, (99-112) DOI: 10.1007/s40618-013-0019-8) 20
Abnormal linear growth in paediatric adrenal diseases: Pathogenesis, prevalence and management 20
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance 19
Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration 17
The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. 16
Role of the mTOR pathway in normal and tumoral adrenal cells. 15
Treatment with GH receptor antagonist in acromegaly:effect on cardiac arrhythmias. 14
The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. 11
The role of mTOR pathway as target for treatment in adrenocortical cancer 11
Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma 11
How should patients with adrenal incidentalomas be followed up? 9
MicroRNAs and Long Non-Coding RNAs in Adrenocortical Carcinoma 7
Somatostatin and somatostatin receptors: from basic concepts to clinical applications. 7
IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer 6
Totale 1.985
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.378
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.378
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20195 0 0 0 0 0 0 0 0 0 2 1 2
2019/2020238 103 1 8 7 12 18 3 4 2 16 31 33
2020/2021192 5 8 23 8 18 34 10 2 21 7 54 2
2021/2022439 6 3 3 5 19 49 9 12 74 28 90 141
2022/2023610 65 42 12 59 81 69 4 57 89 105 16 11
2023/2024209 15 49 40 22 9 18 12 32 7 5 0 0
Totale 1.985